Developer docs
API playgroundTry for free, no card

Search company profiles

Adbiotech

Full company profile

uuid000enl5

Namestring
Adbiotech
Legal namestring
주식회사 애드바이오텍 (ADBIOTECH Co., Ltd.)
Websiteurl
adbiotech.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Adbiotech Co., Ltd. (KOSDAQ: 179530) is a South Korean biotechnology company founded in June 2000 in Chuncheon, Gangwon-do, that develops and commercializes IgY (Immunoglobulin Yolk) antibodies derived from the egg yolks of immunized chickens, alongside a complementary VHH (nanobody) platform derived from camelid heavy-chain antibodies. The company's core proposition is producing high-titer antibodies at manufacturing costs reported as approximately 2,000 times lower than conventional IgG, enabling oral delivery as feed additives for livestock (cattle, swine, poultry) and aquaculture (shrimp, salmon, eel, yellowtail) as antibiotic and vaccine replacements, with selective extension into human health functional foods (Jayeonfore brand) and microbial products (BA-01 platform for food-waste disposers and mold inhibition). It holds 24 registered patents and 5 pending applications, with 25 trademarks including its IgY and VHH brand identities.

The company's go-to-market is primarily B2B, relying on direct sales to large farms and feed companies, an exclusive distribution partnership with Japan's Kyoritsu Pharmaceutical, a wholly-owned China sales subsidiary (AD Qingdao BIO-TECH), and additional distributor networks across approximately 10 countries including Vietnam, Thailand, Malaysia, Taiwan, Mongolia, and Bangladesh. Adbiotech lists more than five distinct revenue streams spanning animal health products, aquaculture pharmaceuticals, human functional foods, microbial/OEM solutions, and partnership royalties — most recently a 2026 co-development agreement with Nasdaq-listed Exicure combining Adbiotech's platform with Burixafor (GPC-100) in sickle cell disease, acute myeloid leukemia, and solid tumors. The company is publicly listed with 60 employees as of 2025 and FY2025 consolidated revenue of KRW 12,897 million; production facility utilization exceeded 100% in Q3 2021, prompting expansion of its Chuncheon manufacturing footprint.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersChuncheon, South Korea
HQ citystring
Chuncheon
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
IgY antibody production, livestock health products, aquaculture disease prevention, VHH nanobody therapeutics, health functional foods
Industry2 codes
PRIMARYHLAAAEAH
Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAMAEAK
Biologics & Immunotherapies (Non-vaccine)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Other Animal Food Manufacturing311119
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Animal health and aquaculture biotechnology
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model5 records
1IgY Animal Health Products
TypeOne Time License
Description

Sale of immunoglobulin yolk (IgY) antibody products for livestock (cattle, pigs, poultry) and aquaculture (shrimp, salmon, eel, yellowtail). Products include feed additives and veterinary pharmaceuticals replacing antibiotics and vaccines. Revenue generated from domestic Korean sales and exports to China, Japan, Vietnam, Thailand, Malaysia, Taiwan, Mongolia.

adbiotech.com
2Aquaculture Products
TypeOne Time License
Description

Specialized aquatic animal health products including Ig-Guard product line for shrimp, salmon, eel, yellowtail. Aqua AD series antibiotics and feed additives for fish farming.

adbiotech.com
3Health Functional Foods
TypeOne Time License
Description

Human health functional food products including Dr. QueenZ Balance (women's health), Dr. KingZ Balance (men's health), Gyngsta Slim (weight management), Sellingus Probiotics. Market expansion into functional food ingredients and individual certification products.

adbiotech.com
4Microbial Products
TypeOne Time License
Description

Food waste disposer microbial products and mold inhibition solutions. Major home appliance company partnerships including LG Electronics for food waste disposer products.

adbiotech.com
5Co-Development Royalties
TypeLicensing Royalties
Description

Potential milestone payments and royalties from co-development agreement with Exicure for Burixafor (GPC-100) combination therapies in oncology and hematology indications.

globenewswire.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 7 records shown
1다살린 (Dasalin)
Description

Livestock functional supplementary feed brand under the IgY product line

adbiotech.com
+6 more records
Core offering1 text field

Adbiotech produces and sells IgY (Immunoglobulin in Yolk) antibody-based feed additives and veterinary pharmaceuticals for livestock (cattle, pig, poultry) and aquaculture (shrimp, salmon, eel, yellowtail), marketed as antibiotic and vaccine alternatives. The company also sells human health functional foods (Jayeonfore brand) and microbial solutions for home appliances (LG partnership), supported by a VHH nanobody co-development program with Exicure. Core technology is egg-based antibody production from immunized chickens covering approximately 300+ pathogen antigens.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • 80%+ reduction in mortality rate in nanobody-treated calves vs control group
+3 more records
Product and service9 records
1Ig-Guard (Salmon)
CategoryAquaculture health products
Description

Feed supplement for salmon aquaculture that prevents and treats SRS disease by replacing antibiotics; efficacy validated at Santiago University field trials for export to Chilean salmon farms.

2Ig-Guard AY (Yellowtail)
CategoryAquaculture health products
Description

Feed supplement that prevents and treats Streptococcus and Nocardia diseases in farmed yellowtail, used as an antibiotic replacement; exclusively exported to Japanese antibiotic-free aquaculture farms.

3Ig-Guard AE (Eel)
CategoryAquaculture health products
Description

Feed supplement that prevents and treats Edwardsiella disease in farmed eel as an antibiotic replacement; exclusively exported to Japanese antibiotic-free aquaculture farms.

4Ig-Guard A (Shrimp)
CategoryAquaculture health products
Description

Feed supplement boosting immunity and productivity in farmed shrimp, preventing and treating AHPND (EMS), WSSV, and WFD diseases as an antibiotic alternative; efficacy verified in university experiments and field trials across China, Thailand, and Vietnam.

5IG-Drink / Ig-Top (Calf oral antibody products)
CategoryLivestock health products
Description

Patented oral solution containing IgY immune protein for newborn calves and goats, marketed for rotavirus diarrhea prevention and immune enhancement; flagship IgY livestock product line sold under the IG-Drink brand.

6M10 (Hailbut) natural anti-parasitic
CategoryAquaculture health products
Description

Natural anti-parasitic agent for cultured flatfish developed jointly with Korea Research Institute of Bioscience and Biotechnology; controls scuticociliate parasites and provides immunity enhancement with no residual toxicity.

7Aqua AD-Gluta / Aqua AD-Neo / Aqua AD-Oxyneo / Aqua AD-Flor
CategoryAquaculture pharmaceuticals
Description

Aquaculture pharmaceutical product lines for treating bacterial diseases (Vibrio, Streptococcus, Edwardsiella) in fish and shrimp including eel, silverfish, trout, carp, yellowtail, and red sea bream.

8Jayeonfore (자연포레) health functional food brand
CategoryHealth functional foods
Description

Health functional food brand offering IgY-based supplements (Dr. QueenZ Balance for menopausal women, Dr. KingZ Balance for men, Gyngsta Slim for weight management, Sellingus Probiotics for gut health) sold through Korean B2C retail and digital channels.

9Burixafor (GPC-100) combination therapy program
CategoryBiopharmaceutical R&D
Description

Co-developed combination therapy assets using Exicure's Burixafor compound combined with Adbiotech's antibody platform targeting sickle cell disease, acute myeloid leukemia, and solid tumor indications for clinical-stage development.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership11 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-04-22
Description

Co-development agreement for Burixafor (GPC-100) combination therapies targeting sickle cell disease, acute myeloid leukemia, and solid tumors. Adbiotech conducts in vivo studies and preclinical validation; Exicure provides Burixafor compound and leads clinical/regulatory strategy. Programs may advance to IND-enabling studies and clinical trials.

Strategic tierMinorTypeOthersAnnounced on2025-06-10
Description

Target of acquisition by OQPBIOM. Quest PharmaTech opposes the acquisition as largest shareholder in OQPBIOM, evaluating legal options.

Strategic tierStrategicTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-02-18
Description

Food waste disposer microbial product partnership with major Korean home appliance manufacturer. 2Q 2025 product launch planned. Also targeting large rental companies as customers for microbial products.

4Jinselbiotech
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2023-06-16
Description

Plant cell culture technology partnership for large-scale nanobody antibody production. Leverages Jinselbiotech's recombinant protein production platform combined with Adbiotech's antibody development capabilities.

adbiotech.com
Strategic tierMinorTypeOthersAnnounced on2023-02-08
Description

Strategic share acquisition of Wiju for business diversification and synergy effects.wiju operates Noljang CONNECT, a traditional market online platform service connecting agricultural product producers directly with merchants.

6Innoback
Strategic tierMinorTypeChannel Partner/ Reseller/ DistributorAnnounced on2022-11-21
Description

Overseas licensing agreement for next-generation swine vaccine products. Adbiotech obtained overseas supply rights for Mycoplasma and Circovirus vaccines from Innoback, expanding animal pharmaceutical pipeline.

7FrontBio
Strategic tierStrategicTypeTechnology or IntegrationAnnounced on2022-09-06
Description

Animal antiviral technology transfer agreement for expanding consumable disease prevention/treatment product pipeline. Focus on swine consumable disease therapeutics.

Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2021-07-16
Description

Industry-academia research center establishment for local microorganism industry development. Joint research on industrial starter culture development and microorganism resource development. Development of BA-01 feed additive for Salmonella control in poultry.

Strategic tierMinorTypeGTM or Marketing PartnerAnnounced on2021-05-04
Description

Marketing partnership with health functional food and pharmaceutical marketing company. Digital IMC advertising agency partnership for health functional food marketing and distribution network expansion.

10Korea Biotechnology Research Institute
Strategic tierStrategicTypeStrategic or Co-development PartnerAnnounced on2020-08-04
Description

Technology transfer for Jeokchongchu (Hovenia dulcis) extract containing functional food ingredients. Transfer of 6 domestic and international patents for joint development of health functional food materials targeting joint health, atopy, and fibrosis. Human clinical trials underway at university hospitals.

adbiotech.com
Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2018-01-01
Description

Japan's largest animal pharmaceutical company (#1 in Japan, #11 globally). Exclusive distribution agreement for livestock, aquaculture, and pet IgY products in Japan since 2018. Strategic investment of approximately 1.2 billion KRW in 2019. Joint R&D and global market expansion collaboration.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Major global animal health company with a livestock portfolio spanning antibiotics, vaccines, and feed additives. Comparable as a broad incumbent in the same animal health customer base, with greater scale but lower specialization in antibody-based alternatives.

TypeDirect peer
Description

Belgium-based clinical-stage biotech pioneering VHH/nanobody therapeutics (efgartigimod). Closest technology peer to Adbiotech's VHH nanobody platform, demonstrating the commercial potential of camelid-derived single-domain antibodies in human therapeutics.

TypeBroad incumbent
Description

Diversified animal health and nutrition company with livestock pharmaceutical and feed additive products. Comparable as a broad incumbent in the same livestock health and nutrition category where Adbiotech competes.

TypeRegional player
Description

Hong Kong-listed pharmaceutical company with veterinary and animal health products across Asia. Comparable as a regional animal health peer in the same Asian distribution geography where Adbiotech's Kyoritsu and China subsidiary operate.

TypeEmerging player
Description

Provider of camelid VHH/nanobody reagents and services for research and diagnostics. Comparable as a niche player in the same VHH/nanobody technology space, though focused on research reagents rather than therapeutics.

TypeDirect peer
Description

Germany-based animal nutrition company with a significant IgY antibody product line (Globigen) targeting livestock gut health and disease prevention — directly comparable as IgY-based antibiotic-alternative feed additives serving the same livestock customer base.

TypeBroad incumbent
Description

Largest global animal health company offering vaccines, parasiticides, and diagnostics across livestock and companion animals. Overlaps with Adbiotech's livestock therapeutics franchise as a broad incumbent with established distribution channels and regulatory expertise.

TypeBroad incumbent
Description

Independent global animal health company with strong aquaculture and livestock pharmaceutical offerings, particularly in Asia. Comparable as a broad incumbent with overlapping aquaculture health products similar to Adbiotech's Ig-Guard line.

TypeEmerging player
Description

US-based IgY antibody company focused on human and animal health applications including immune support. Comparable as a niche IgY peer operating in a similar product category, though smaller and earlier-stage than Adbiotech.

TypeDirect peer
Description

Original pioneer of VHH/nanobody technology acquired by Sanofi for ~$4.8B. The Ablynx platform pioneered camelid-derived single-domain antibodies — the same technological foundation as Adbiotech's VHH franchise, making it the canonical nanobody comparable.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers5 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile5 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Adbiotech

Animal health and aquaculture biotechnologyadbiotech.com

What Adbiotech does

Adbiotech Co., Ltd. (KOSDAQ: 179530) is a South Korean biotechnology company founded in June 2000 in Chuncheon, Gangwon-do, that develops and commercializes IgY (Immunoglobulin Yolk) antibodies derived from the egg yolks of immunized chickens, alongside a complementary VHH (nanobody) platform derived from camelid heavy-chain antibodies. The company's core proposition is producing high-titer antibodies at manufacturing costs reported as approximately 2,000 times lower than conventional IgG, enabling oral delivery as feed additives for livestock (cattle, swine, poultry) and aquaculture (shrimp, salmon, eel, yellowtail) as antibiotic and vaccine replacements, with selective extension into human health functional foods (Jayeonfore brand) and microbial products (BA-01 platform for food-waste disposers and mold inhibition). It holds 24 registered patents and 5 pending applications, with 25 trademarks including its IgY and VHH brand identities.

The company's go-to-market is primarily B2B, relying on direct sales to large farms and feed companies, an exclusive distribution partnership with Japan's Kyoritsu Pharmaceutical, a wholly-owned China sales subsidiary (AD Qingdao BIO-TECH), and additional distributor networks across approximately 10 countries including Vietnam, Thailand, Malaysia, Taiwan, Mongolia, and Bangladesh. Adbiotech lists more than five distinct revenue streams spanning animal health products, aquaculture pharmaceuticals, human functional foods, microbial/OEM solutions, and partnership royalties — most recently a 2026 co-development agreement with Nasdaq-listed Exicure combining Adbiotech's platform with Burixafor (GPC-100) in sickle cell disease, acute myeloid leukemia, and solid tumors. The company is publicly listed with 60 employees as of 2025 and FY2025 consolidated revenue of KRW 12,897 million; production facility utilization exceeded 100% in Q3 2021, prompting expansion of its Chuncheon manufacturing footprint.

Adbiotech firmographics

Firmographics
Name
Adbiotech
Legal name
주식회사 애드바이오텍 (ADBIOTECH Co., Ltd.)
Website
https://adbiotech.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Adbiotech industry classification

Industry
Product category
Animal health and aquaculture biotechnology
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Other Animal Food Manufacturing (311119)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAAAEAH
Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAMAEAK
Biologics & Immunotherapies (Non-vaccine)
Healthcare & Life Sciences/Veterinary & Animal Health/Veterinary Pharmaceuticals & Biologics

Keywords

  • IgY antibody production
  • Livestock health products
  • Aquaculture disease prevention
  • VHH nanobody therapeutics
  • Health functional foods

Where Adbiotech is headquartered

Location

Headquarters

HQ city
Chuncheon
HQ country
South Korea
HQ region
Asia

Offices3 records

Markets served

Adbiotech business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales

Revenue model

  1. IgY Animal Health Products: Sale of immunoglobulin yolk (IgY) antibody products for livestock (cattle, pigs, poultry) and aquaculture (shrimp, salmon, eel, yellowtail). Products include feed additives and veterinary pharmaceuticals replacing antibiotics and vaccines. Revenue generated from domestic Korean sales and exports to China, Japan, Vietnam, Thailand, Malaysia, Taiwan, Mongolia.
  2. Aquaculture Products: Specialized aquatic animal health products including Ig-Guard product line for shrimp, salmon, eel, yellowtail. Aqua AD series antibiotics and feed additives for fish farming.
  3. Health Functional Foods: Human health functional food products including Dr. QueenZ Balance (women's health), Dr. KingZ Balance (men's health), Gyngsta Slim (weight management), Sellingus Probiotics. Market expansion into functional food ingredients and individual certification products.
  4. Microbial Products: Food waste disposer microbial products and mold inhibition solutions. Major home appliance company partnerships including LG Electronics for food waste disposer products.
  5. Co-Development Royalties: Potential milestone payments and royalties from co-development agreement with Exicure for Burixafor (GPC-100) combination therapies in oncology and hematology indications.

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Adbiotech product offering

Product offering

Core offering

Adbiotech produces and sells IgY (Immunoglobulin in Yolk) antibody-based feed additives and veterinary pharmaceuticals for livestock (cattle, pig, poultry) and aquaculture (shrimp, salmon, eel, yellowtail), marketed as antibiotic and vaccine alternatives. The company also sells human health functional foods (Jayeonfore brand) and microbial solutions for home appliances (LG partnership), supported by a VHH nanobody co-development program with Exicure. Core technology is egg-based antibody production from immunized chickens covering approximately 300+ pathogen antigens.

Differentiator

Problem solved

Functional benefit

Brands

  • 다살린 (Dasalin): Livestock functional supplementary feed brand under the IgY product line
  • 팜피온 (Farmpion)
  • 자연포레 (자연포레 / Jayeonfore)
  • Ig-Drink / Ig-Top
  • Ig-Guard
  • 아이지드링크 (IG-Drink)
  • Aqua AD-Gluta / Aqua AD-Ne o / Aqua AD-Oxyneo / Aqua AD-Flor

Products and services

  • Ig-Guard (Salmon) Feed supplement for salmon aquaculture that prevents and treats SRS disease by replacing antibiotics; efficacy validated at Santiago University field trials for export to Chilean salmon farms.
  • Ig-Guard AY (Yellowtail) Feed supplement that prevents and treats Streptococcus and Nocardia diseases in farmed yellowtail, used as an antibiotic replacement; exclusively exported to Japanese antibiotic-free aquaculture farms.
  • Ig-Guard AE (Eel) Feed supplement that prevents and treats Edwardsiella disease in farmed eel as an antibiotic replacement; exclusively exported to Japanese antibiotic-free aquaculture farms.
  • Ig-Guard A (Shrimp) Feed supplement boosting immunity and productivity in farmed shrimp, preventing and treating AHPND (EMS), WSSV, and WFD diseases as an antibiotic alternative; efficacy verified in university experiments and field trials across China, Thailand, and Vietnam.
  • IG-Drink / Ig-Top (Calf oral antibody products) Patented oral solution containing IgY immune protein for newborn calves and goats, marketed for rotavirus diarrhea prevention and immune enhancement; flagship IgY livestock product line sold under the IG-Drink brand.
  • M10 (Hailbut) natural anti-parasitic Natural anti-parasitic agent for cultured flatfish developed jointly with Korea Research Institute of Bioscience and Biotechnology; controls scuticociliate parasites and provides immunity enhancement with no residual toxicity.
  • Aqua AD-Gluta / Aqua AD-Neo / Aqua AD-Oxyneo / Aqua AD-Flor Aquaculture pharmaceutical product lines for treating bacterial diseases (Vibrio, Streptococcus, Edwardsiella) in fish and shrimp including eel, silverfish, trout, carp, yellowtail, and red sea bream.
  • Jayeonfore (자연포레) health functional food brand Health functional food brand offering IgY-based supplements (Dr. QueenZ Balance for menopausal women, Dr. KingZ Balance for men, Gyngsta Slim for weight management, Sellingus Probiotics for gut health) sold through Korean B2C retail and digital channels.
  • Burixafor (GPC-100) combination therapy program Co-developed combination therapy assets using Exicure's Burixafor compound combined with Adbiotech's antibody platform targeting sickle cell disease, acute myeloid leukemia, and solid tumor indications for clinical-stage development.

Quantifiable outcome

  • 80%+ reduction in mortality rate in nanobody-treated calves vs control group
  • +3 more outcomes

Companies that use Adbiotech

Customer profile

Named customers5 records

Segments5 records

Ideal customer profiles5 records

Adbiotech technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Adbiotech partnerships and signals

Strategic signal

Partnerships

Eleven partnerships are on record, tiered core, minor and strategic.

  • Exicure, Inc.coreStrategic or Co-development Partner · 22 April 2026Co-development agreement for Burixafor (GPC-100) combination therapies targeting sickle cell disease, acute myeloid leukemia, and solid tumors. Adbiotech conducts in vivo studies and preclinical validation; Exicure provides Burixafor compound and leads clinical/regulatory strategy. Programs may advance to IND-enabling studies and clinical trials.
  • OQPBIOM Inc.minorOthers · 10 June 2025Target of acquisition by OQPBIOM. Quest PharmaTech opposes the acquisition as largest shareholder in OQPBIOM, evaluating legal options.
  • LG ElectronicsstrategicChannel Partner/ Reseller/ Distributor · 18 February 2025Food waste disposer microbial product partnership with major Korean home appliance manufacturer. 2Q 2025 product launch planned. Also targeting large rental companies as customers for microbial products.
  • JinselbiotechstrategicTechnology or Integration · 16 June 2023Plant cell culture technology partnership for large-scale nanobody antibody production. Leverages Jinselbiotech's recombinant protein production platform combined with Adbiotech's antibody development capabilities.
  • WijuminorOthers · 8 February 2023Strategic share acquisition of Wiju for business diversification and synergy effects.wiju operates Noljang CONNECT, a traditional market online platform service connecting agricultural product producers directly with merchants.
  • InnobackminorChannel Partner/ Reseller/ Distributor · 21 November 2022Overseas licensing agreement for next-generation swine vaccine products. Adbiotech obtained overseas supply rights for Mycoplasma and Circovirus vaccines from Innoback, expanding animal pharmaceutical pipeline.
  • FrontBiostrategicTechnology or Integration · 6 September 2022Animal antiviral technology transfer agreement for expanding consumable disease prevention/treatment product pipeline. Focus on swine consumable disease therapeutics.
  • Kangwon National UniversitystrategicStrategic or Co-development Partner · 16 July 2021Industry-academia research center establishment for local microorganism industry development. Joint research on industrial starter culture development and microorganism resource development. Development of BA-01 feed additive for Salmonella control in poultry.
  • ThinkCreativeminorGTM or Marketing Partner · 4 May 2021Marketing partnership with health functional food and pharmaceutical marketing company. Digital IMC advertising agency partnership for health functional food marketing and distribution network expansion.
  • Korea Biotechnology Research InstitutestrategicStrategic or Co-development Partner · 4 August 2020Technology transfer for Jeokchongchu (Hovenia dulcis) extract containing functional food ingredients. Transfer of 6 domestic and international patents for joint development of health functional food materials targeting joint health, atopy, and fibrosis. Human clinical trials underway at university hospitals.
  • Kyoritsu Pharmaceutical (共立製藥)coreChannel Partner/ Reseller/ Distributor · 1 January 2018Japan's largest animal pharmaceutical company (#1 in Japan, #11 globally). Exclusive distribution agreement for livestock, aquaculture, and pet IgY products in Japan since 2018. Strategic investment of approximately 1.2 billion KRW in 2019. Joint R&D and global market expansion collaboration.

Scale indicators9 records

Recent moves6 records

Expansion highlights7 records

Adbiotech competitors and assessment

Company assessment

Broad incumbents

  • Elanco Animal Health: Major global animal health company with a livestock portfolio spanning antibiotics, vaccines, and feed additives. Comparable as a broad incumbent in the same animal health customer base, with greater scale but lower specialization in antibody-based alternatives.
  • Phibro Animal Health: Diversified animal health and nutrition company with livestock pharmaceutical and feed additive products. Comparable as a broad incumbent in the same livestock health and nutrition category where Adbiotech competes.
  • Zoetis: Largest global animal health company offering vaccines, parasiticides, and diagnostics across livestock and companion animals. Overlaps with Adbiotech's livestock therapeutics franchise as a broad incumbent with established distribution channels and regulatory expertise.
  • Virbac: Independent global animal health company with strong aquaculture and livestock pharmaceutical offerings, particularly in Asia. Comparable as a broad incumbent with overlapping aquaculture health products similar to Adbiotech's Ig-Guard line.

Direct peers

  • Argenx: Belgium-based clinical-stage biotech pioneering VHH/nanobody therapeutics (efgartigimod). Closest technology peer to Adbiotech's VHH nanobody platform, demonstrating the commercial potential of camelid-derived single-domain antibodies in human therapeutics.
  • EW Nutrition: Germany-based animal nutrition company with a significant IgY antibody product line (Globigen) targeting livestock gut health and disease prevention — directly comparable as IgY-based antibiotic-alternative feed additives serving the same livestock customer base.
  • Ablynx (Sanofi): Original pioneer of VHH/nanobody technology acquired by Sanofi for ~$4.8B. The Ablynx platform pioneered camelid-derived single-domain antibodies — the same technological foundation as Adbiotech's VHH franchise, making it the canonical nanobody comparable.

Regional players

  • Lee's Pharmaceutical: Hong Kong-listed pharmaceutical company with veterinary and animal health products across Asia. Comparable as a regional animal health peer in the same Asian distribution geography where Adbiotech's Kyoritsu and China subsidiary operate.

Emerging players

  • CAMPRO Scientific (nanobody reagents): Provider of camelid VHH/nanobody reagents and services for research and diagnostics. Comparable as a niche player in the same VHH/nanobody technology space, though focused on research reagents rather than therapeutics.
  • Imunova (IgY Nutrition): US-based IgY antibody company focused on human and animal health applications including immune support. Comparable as a niche IgY peer operating in a similar product category, though smaller and earlier-stage than Adbiotech.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

Adbiotech financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Adbiotech leadership team

Management profile

Number of profiles

Profiles1 record

Adbiotech subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Adbiotech funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Adbiotech M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Adbiotech

What does Adbiotech do?

Adbiotech produces and sells IgY (Immunoglobulin in Yolk) antibody-based feed additives and veterinary pharmaceuticals for livestock (cattle, pig, poultry) and aquaculture (shrimp, salmon, eel, yellowtail), marketed as antibiotic and vaccine alternatives. The company also sells human health functional foods (Jayeonfore brand) and microbial solutions for home appliances (LG partnership), supported by a VHH nanobody co-development program with Exicure. Core technology is egg-based antibody production from immunized chickens covering approximately 300+ pathogen antigens.

Is Adbiotech a public or private company?

Adbiotech is a public company. It is classified as public and is currently operating.

When was Adbiotech founded?

Adbiotech was founded in 2000. It employs 1 to 10 people.

Where is Adbiotech based?

Adbiotech is headquartered in Chuncheon, South Korea, in the Asia region.

How does Adbiotech make money?

Five revenue lines are on record. IgY Animal Health Products are the primary driver. The others are aquaculture Products, health Functional Foods, microbial Products and co-Development Royalties.

Who are Adbiotech's main competitors?

Broad incumbents on record are Elanco Animal Health, Phibro Animal Health, Zoetis and Virbac. Direct peers are Argenx, EW Nutrition and Ablynx (Sanofi). Lee's Pharmaceutical is listed as a regional player. Emerging players are CAMPRO Scientific (nanobody reagents) and Imunova (IgY Nutrition).

Does Adbiotech have an API?

No public API is recorded for Adbiotech.

What industry is Adbiotech in?

Adbiotech's product category is Animal health and aquaculture biotechnology. Its primary akta.pro industry code is HLAAAEAH, Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins), with a secondary code of HLAMAEAK, Biologics & Immunotherapies (Non-vaccine). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The future of tradingADBiotech Calls Extraordinary Shareholders MeetingADBiotech will hold an extraordinary shareholders meeting on Dec. 18, 2026, at 9 a.m. at its headquarters in Chuncheon. The meeting was announced via DART on Nov. 11, 2026, with no further details provided.NateNGenBio Hits Limit; Financing Splits Proteina, AdBioTech[K-Bio Pulse] : 네이트 뉴스NGenBio hit its daily upper limit at 804 won after announcing a patent for NGS technology, while Proteina surged 23.7% on a 36.5 billion won financing plan. AdBioTech fell 18.5% on bond delays and dilution risks. NGenBio remains under a regulatory warning, and Proteina's financing faces uncertainty.NaverNGenBio Hits Limit; Financing Splits Proteina, AdBioTech[K-Bio Pulse]South Korean biotech stocks diverged on Nov 5: NGenBio hit the upper limit after announcing a leukemia-diagnostics patent, Proteina surged 23.7% on a 36.5 billion won financing plan, and AdBioTech fell 18.5% after delaying convertible bond payments and adding dilution risks.The future of tradingADBiotech investor OpusOne Investment Partnership discloses 7.15% stake, 7.15% voting rightsOpusOne Investment Partnership disclosed a 7.15% stake in ADBiotech, representing 2,225,932 voting shares. The position was built through an OTC purchase of convertible bonds, converted into voting shares on Sept. 1, 2026. The filing cited passive investment intent.GlobeNewswireExicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)Exicure, Inc. announced a co-development agreement with Adbiotech Co., Ltd., a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) for sickle cell disease, acute myeloid leukemia, and solid tumors. Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation while Exicure will provide Burixafor and lead clinical and regulatory strategy. The parties intend to conduct in vivo validation studies and may advance selected programs into IND-enabling studies and clinical trials, subject to a subsequent definitive agreement and potential funding.Stock TitanExicure, Adbiotech sign Burixafor co-development dealExicure, Inc. (Nasdaq: XCUR) has entered into a co-development agreement with Adbiotech Co., Ltd. (KOSDAQ: 179530), a Korea-based biotechnology company, to explore combination therapies based on Burixafor (GPC-100) in sickle cell disease, acute myeloid leukemia, and solid tumors. Under the agreement, Adbiotech will conduct in vivo studies and support preclinical validation while Exicure will provide Burixafor and lead clinical and regulatory strategy. The parties intend to advance selected programs into IND-enabling studies and clinical trials, subject to further agreement, and plan to secure funding to support future clinical development.GlobeNewswireQuest PharmaTech Announces Opposition to OQPBIOM's Acquisition of AdBioTechQuest PharmaTech announced it opposes OQPBIOM's acquisition of a controlling interest in AdBioTech, a vehicle for advancing oregovomab's clinical trials. Quest, OQPBIOM's largest shareholder with a 26.25% stake, was not informed or consulted and is consulting advisors on legal options.PharmnewsAedbiotech acquires stake in agricultural product distribution platform... Seeking business diversification - Farm NewsImmunotherapy specialist Adbiotech has secured management rights and become the largest shareholder of Wiju by acquiring shares through a third-party allocation. Wiju operates 'NoljangCONNECT', an online platform that connects agricultural and fishery producers directly with consumers to simplify distribution. Adbiotech expects business synergy and profit improvement from this strategic diversification into the agricultural product distribution sector.